EGFR and neoplasm: Importantly, in contrast to the hematological malignancies, these mutations did not compromise the ubiquitination of EGFR, yet increased the survival, proliferation and motility of cancer cells, thereby suggesting other mediators for the tumor growth and metastatic enhancing properties of those mutants [22].